Abstract: Disclosed herein are several embodiments of a negative pressure system and methods of using the same in the treatment of wounds. Some embodiments are directed to a system that utilizes a wound dressing with at least three layers. These embodiments are directed toward improved distribution of negative pressure to a wound and periwound site surrounding the wound.

Abstract: Pyridopyrazine compounds which are suitable for the treatment or prevention of physiological and/or pathophysiological states mediated and/or modulated by signal transduction pathways and/or enzymes in mammals and in particular in humans.

Abstract: The invention relates to novel pyrido[2,3-b]pyrazine derivatives of the general formulae (I) and (II), and to their preparation and use as medicaments, especially for the treatment of malignant disorders and other disorders based on pathological cell proliferations.

Abstract: The invention provides quinoxalines of the general formula I which are used as medicaments preferably for treating tumour disorders, in particular in cases of drug resistance to other active compounds and in cases of metastasic carcinoma. The possible applications are not limited to tumour disorders.

Abstract: The invention relates to novel pyrido[2,3-b]pyrazine derivatives of the general formulae (I) and (II), and to their preparation and use as medicaments, especially for the treatment of malignant disorders and other disorders based on pathological cell proliferations.

Abstract: The invention relates to pyrido[2,3-b]pyrazines of the general formulae (I) and (II), and to their preparation and use as medicaments, especially for the treatment of malignant disorders and other disorders based on pathological cell proliferations.

Abstract: The invention provides quinoxalines of the general formula I which are used as medicaments preferably for treating tumour disorders, in particular in cases of drug resistance to other active compounds and in cases of metastasic carcinoma. The possible applications are not limited to tumour disorders.

Abstract: The invention relates to novel pyrido[2,3-b]pyrazine derivatives of the general formulae (I) and (II), and to their preparation and use as medicaments, especially for the treatment of malignant disorders and other disorders based on pathological cell proliferations.

Abstract: The present invention provides new pyridopyrazine compounds which are suitable for the treatment or prevention of physiological and/or pathophysiological states mediated and/or modulated by signal transduction pathways and/or enzymes in mammals and in particular in humans.

Abstract: Methods and compositions for modulating glucose transport are provided herein.

Abstract: Methods and compositions for modulating glucose transport are provided herein.

Abstract: Inhibition of RIP140 increases glucose transport. Compounds that inhibit RIP140 expression or activity are useful for treating disorders associated with aberrant glucose transport (e.g., diabetes), treating obesity, increasing metabolism (e.g., fatty acid metabolism), and increasing brown fat.

Abstract: Methods of identifying insulin response modulators are provided. In particular, methods that feature identifying modulators of Akt and its associated substrates (including R-type calcium channel alpha-1E subunit (R-CaC1E), WNK1, FMS interacting protein (FMIP), nGAP-like protein, nuclear matrix protein p84, HIRA interacting protein 3 (HIRIP3), HSP71, ribosomal protein L6, guanine nucleotide exchange factor Lbc (GEF Lbc), ATP citrate lyase, Mi-2b, peripheral benzodiazepine receptor-associated protein 1, heterogeneous nuclear ribonucleoprotein U (hnRNP U protein), pyruvate carboxylase precursor, Eps domain containing protein (RalBP1), nonmuscle myosin IIA (NMMIIA), and stress 70 protein (p66 mot1/GRP75), or activities associated therewith, are provided. Therapeutic methods utilizing compounds identified according to the methods of the invention are also provided.

Abstract: The instant invention provides polypeptides comprising variant pleckstrin homology (PH) domains. The invention provides polypeptides having increased or decreased binding specificity for a phosphatidylinositide molecule to which the PH domain naturally binds. Further, the invention provides polypeptides having increased binding specificity for a phosphatidylinositide molecule to which the PH domain naturally does not bind.

Abstract: Nucleotide sequences and amino acid sequences from nucleic acids and proteins involved in glucose transport are disclosed. The sequences are useful for producing DNA arrays that can be used for the diagnosis of, predictive testing for, and development of treatments for disorders involving glucose transport such as type II diabetes.

Abstract: In general, it has been difficult to introduce nucleic acid sequences into adipocytes. Methods are described for introducing nucleic acids such as siRNAs into adipocytes, including the introduction of sequences targeting Akt1, Akt2 and Myo1c. Methods for identifying genes involved in glucose transport and for identifying insulin response modulators are described. Therapeutic methods are also provided.

Abstract: The invention relates to novel acridine derivatives of the formula 1, to their preparation and to their use as medicaments, in particular for the treatment of tumors.